Navigation Links
BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
Date:7/29/2008

. Koestler, Ph.D., executive vice president and president of Schering-Plough Research Institute. "This is the first major approval of a product from our combination with Organon BioSciences and is a significant achievement for Schering-Plough. This further validates the value of our combination, which closed in November 2007, and is already making a positive contribution to our business."

BRIDION has a rapid onset and, in addition to routine reversal, can be used in critical situations when immediate reversal of rocuronium is needed. In BRIDION clinical studies, the median time to reversal of rocuronium was about three minutes.

A muscle relaxant plays several critical roles in general anesthesia. Anesthesiologists use muscle relaxation to improve surgical conditions and to facilitate intubation and mechanical ventilation. Reversal agents reverse the effects of muscle relaxants, enabling patients to regain normal muscle function sooner and breathe on their own. Current reversal agents are slow and are associated with certain undesirable side effects, including cardiac rhythm disturbances and gastrointestinal and pulmonary side effects.

"The ability to rapidly reverse both moderate and deep levels of muscle relaxation during general anesthesia was not possible before BRIDION," said Rajinder Mirakhur, M.D., professor of anesthetics at The Queen's University of Belfast, Northern Ireland, and a principal investigator in the BRIDION clinical trials program. "BRIDION can provide us with greater flexibility to induce and maintain the level of muscle relaxation with rocuronium or vecuronium necessary throughout surgery and reverse that relaxation quickly when needed."

BRIDION (sugammadex) Clinical Trials

The EC approval of BRIDION is based on an extensive clinical trial database of approximately 1,800 patients and volunteers, including data from the SIGNAL, AURORA and SPECTRUM clinical trials. The SIGNAL trial involved adult patients underg
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
2. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
3. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
4. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
7. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
8. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
9. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
10. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
11. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015  Perrigo Company plc ("Perrigo") ... has completed the acquisition of leading OTC brands from ... million. The transaction is a clear demonstration of Perrigo,s ... leading European distribution network spanning 36 countries.  ... Papa commented, "We are excited to complete this ...
(Date:8/28/2015)... PUNE, India , August 28, 2015 ... Essential Oils), Livestock (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by ... , Asia-Pacific , and Rest of ... by MarketsandMarkets, The global market for Eubiotics was valued at ... USD 7.05 Billion by 2020, at a CAGR of 7.4% ...
(Date:8/27/2015)... ALEXANDRIA, Va. , Aug. 27, 2015 /PRNewswire-USNewswire/ ... in the Food and Drug Administration,s (FDA,s) draft ... including reference products and biosimilars, to bear a ... years, AMCP has been seeking a decision from ... joined 18 diverse health care stakeholders urging the ...
Breaking Medicine Technology:Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2
(Date:8/30/2015)... Fl (PRWEB) , ... August 30, 2015 , ... ... Spector has joined the company as the new Global Communications Director for InHealth ... public relations experience having spent the last 16 years doing on-air television, producing ...
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... Natural Rest ... beneficial effects as sleep aids and calming remedies, which help to improve mood disorders ... of a great deal of research in the field of regenerative medicine conducted by ...
(Date:8/30/2015)... ... August 30, 2015 , ... Certified Nutrition Businessman Reid Eckert agrees ... and InHealth media is a global sales and communications firm that offers U.S. brands ... continue our business relationship with Mr. Reid Eckert, as his interpretation of the nutritional ...
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional Products International ... the expansion of global cosmeceutical and skin care brands. Mr. Fernandez comes ... last 25 years working in operations, purchasing and management for some of the ...
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional ... from Administrative assistant to Executive Assistant to CEO Mitch Gould for Nutritional Products ... focused on your goals. Kathleen graduated from Florida State University with a ...
Breaking Medicine News(10 mins):Health News:InHealth Media Appoints New Global Communications Director 2Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:NPI Appoints New Executive Assistant To CEO 2
... , FRIDAY, Dec. 30 (HealthDay News) -- ... and skaters should take simple safety precautions, orthopedic experts ... that in 2010 more than 440,000 people were treated ... among snowboarders and skiers. These two sports accounted for ...
... Two recent studies by Van Andel Research Institute scientists ... distinct kidney cancer subtypes, which could pave the way for ... Cell led by Kyle Furge, Ph.D. and Aikseng Ooi, ... of Type 2 papillary renal cell carcinoma (PRCC2), an aggressive ...
... Dennis Thompson HealthDay Reporter , THURSDAY, Dec. 29 (HealthDay ... was 19 years old. Then a sophomore studying physics at ... and depression for years. He said he,d self-medicated by drinking and ... demons that had been gnawing at his soul for years burst ...
... 2011 revision of the International Standards for the Neurological ... the November 2011 issue of the Journal of ... Steven Kirshblum et al clarifies the modifications to this ... http://www.ingentaconnect.com/content/maney/scm (#6, Nov 2011). ISNCSCI ...
... -- A new review of existing research suggests that, despite ... heart patients should get Plavix, a blood-thinning drug used to ... clopidogrel, is used to treat or prevent blood clots due ... as balloon angioplasty. But some patients ...
... Dennis Thompson HealthDay Reporter , WEDNESDAY, Dec. 28 ... are typically thought to be diseases of young women and ... drive a young person to an eating disorder may linger ... are coming forward to receive treatment for eating problems that ...
Cached Medicine News:Health News:Tips to Keep Winter Sports Injury-Free 2Health News:Tips to Keep Winter Sports Injury-Free 3Health News:Van Andel Research Institute findings provide more complete picture of kidney cancer 2Health News:Virginia Man Won't Let His Mental Illness Define Him 2Health News:JSCM publishes revised International Standards for Neurological Classification of Spinal Cord Injury 2Health News:Doubt Cast on Use of Genetic Test Before Plavix 2Health News:Eating Disorders Can Last Well Beyond Teen Years 2Health News:Eating Disorders Can Last Well Beyond Teen Years 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: